BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38795114)

  • 1. The impact of infused red blood cell volume on major and bidirectional ABO-mismatched bone marrow transplantation.
    Araújo AB; Schmalfuss T; Furlan JM; Speransa D; Angeli MH; Sekine L; Franz JPM
    Cytotherapy; 2024 May; ():. PubMed ID: 38795114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source.
    Damodar S; Shanley R; MacMillan M; Ustun C; Weisdorf D
    Biol Blood Marrow Transplant; 2017 May; 23(5):795-804. PubMed ID: 28232088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants.
    Mehta P; Ramprakash S; Raghuram CP; Trivedi D; Dhanya R; Agarwal RK; Faulkner L
    Ann Hematol; 2021 Aug; 100(8):2071-2078. PubMed ID: 34148110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Anti-A/B isoagglutinin titers of IgG class, but not of IgM, are associated with increased red blood cell transfusion requirements in bone marrow transplantation with major ABO-mismatch.
    De Santis GC; Garcia-Silva AC; Dotoli GM; de Castro PT; Simões BP; Covas DT
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28160319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ABO-incompatible allogeneic bone marrow transplantation].
    Xu L; Guo N; Wang S
    Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):413-5. PubMed ID: 11721421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
    Ataca Atilla P; Akkus E; Atilla E; Gokmen N; Civriz Bozdag S; Kocak Toprak S; Kurt Yuksel M; Ozcan M; Demirer T; Ilhan O; Beksac M; Akan H; Arslan O; Topcuoglu P; Gurman G
    Transfus Clin Biol; 2020 Aug; 27(3):115-121. PubMed ID: 32659269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
    Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
    Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kobayashi T; Sato A; Iseki T; Yamaguchi T; Tojo A; Asano S
    Bone Marrow Transplant; 2007 Sep; 40(6):523-8. PubMed ID: 17646845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
    Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
    Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.
    Stussi G; Halter J; Bucheli E; Valli PV; Seebach L; Gmür J; Gratwohl A; Schanz U; Passweg JR; Seebach JD
    Haematologica; 2009 Feb; 94(2):239-48. PubMed ID: 19144657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of ABO incompatibility in multiple myeloma patients undergoing peripheral blood stem cell transplantation after reduced intensity conditioning.
    Marenchino D; Maddalena L; Balbo R; Avonto I; Menardi G; Prucca M; Perotti L; Mordini N; Peano G
    Blood Transfus; 2011 Jan; 9(1):79-85. PubMed ID: 21084015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.
    Badros A; Tricot G; Toor A; Morris C; Guo C; Munshi N; Barlogie B; Cottler-Fox M
    Transfusion; 2002 Feb; 42(2):205-9. PubMed ID: 11896336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant.
    Quek J; Lee JJ; Lim FL; Diong C; Goh YT; Gopalakrishnan S; Ho A; Hwang W; Koh M; Loh Y; Linn YC
    Transfusion; 2019 Jan; 59(1):335-339. PubMed ID: 30467850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion.
    Patrick K; Lau W; Gassas A; McDougall E; Doyle J; Ali M; Krueger J; Courtney S; Armstrong C; Egeler RM; Schechter T
    Bone Marrow Transplant; 2015 Apr; 50(4):536-9. PubMed ID: 25621802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion hemolysis after pediatric major ABO-mismatched bone marrow transplant: Comparison of two red blood cell depletion techniques.
    Nickel RS; Qayed M; Worthington-White D; Stowell SR; Chiang KY
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies.
    Chen Y; Wan X; Cao Y; Wang H; Han D; Zhang Y; Yao W; Song K; Fan Q; Zhu X; Sun Z; Liu H
    Blood Transfus; 2022 Mar; 20(2):156-167. PubMed ID: 34369864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation.
    Gmür JP; Burger J; Schaffner A; Neftel K; Oelz O; Frey D; Metaxas M
    Blood; 1990 Jan; 75(1):290-5. PubMed ID: 2294993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.
    Maciej Zaucha J; Mielcarek M; Takatu A; Little MT; Gooley T; Baker J; Maloney DG; Sandmaier BM; Maris M; Chauncey T; Storb R; Torok-Storb B
    Br J Haematol; 2002 Dec; 119(3):740-50. PubMed ID: 12437653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.